Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02009865 · ClinicalTrials.gov registry record · Phase 3
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 379
- Enrollment target
NCT02009865 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 379 participants.
The verdict
NCT02009865, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 379 participants
- Enrollment target
Study Summary
This is a double-blind, randomized, olive oil-controlled study to investigate the efficacy and safety of Epanova as an adjunct therapy to diet for reduction of TG levels in subjects with severe hypertriglyceridemia. The study consists of an approximately 8-week screening period that includes a diet and lifestyle stabilization and washout period and a 12-week treatment period.
Interventions
- DRUG Olive Oil
- DRUG Epanova
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 379 participants |
| Start Date | 2013-12-16 |
| Est. Completion | 2014-12-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02009865
The ClinicalTrials.gov registry entry for NCT02009865 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 379 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olive Oil is the first listed.
NCT02009865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02009865 about?
NCT02009865 is a clinical study titled "Epanova® for Lowering Very High Triglycerides II (EVOLVE II)". This is a double-blind, randomized, olive oil-controlled study to investigate the efficacy and safety of Epanova as an adjunct therapy to diet for reduction of TG levels in subjects with severe hypertriglyceridemia. The study consists of an approximately 8-week screening period that includes a diet ...
What is the current status of trial NCT02009865?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 379 participants. The study started on 2013-12-16. Estimated completion is 2014-12-23.
What interventions are being tested in trial NCT02009865?
The interventions under investigation include: Olive Oil (DRUG), Epanova (DRUG).
Who is sponsoring clinical trial NCT02009865?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.